Showing results (21-30 of 38) with videos related to
Sort By:
Pageof 4
Pediatric Blood & Cancer|September 19, 2017
Hepatoblastoma in children aged less than six months at diagnosis: A report from the SIOPEL groupPatrizia Dall'Igna, Laurence Brugieres, Anne Sanlaville Christin, et al.European Journal of Cancer (Oxford, England : 1990)|December 12, 2018
Microscopically positive resection margin after hepatoblastoma resection: what is the impact on prognosis? A Childhood Liver Tumours Strategy Group (SIOPEL) reportDaniel C Aronson, Víola B Weeda, Rudolf Maibach, et al.European Journal of Cancer (Oxford, England : 1990)|January 17, 2012
Prognostic stratification for children with hepatoblastoma: the SIOPEL experienceRudolf Maibach, Derek Roebuck, Laurence Brugieres, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2010
Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR studyJózsef Zsíros, Rudolf Maibach, Elizabeth Shafford, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 5, 2014
Neuroblastoma mRNAs predict outcome in children with stage 4 neuroblastoma: a European HR-NBL1/SIOPEN studyVirginie F Viprey, Walter M Gregory, Maria V Corrias, et al.Mabs|November 10, 2017
Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD<sub>2</sub> antibody ch14.18/CHOIna Mueller, Karoline Ehlert, Stefanie Endres, et al.Pharmacogenetics and Genomics|April 27, 2017
TPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatin-induced ototoxicitySigne Thiesen, Peng Yin, Andrea L Jorgensen, et al.The Lancet. Oncology|July 9, 2013
Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility studyJózsef Zsiros, Laurence Brugieres, Penelope Brock, et al.The New England Journal of Medicine|October 23, 2009
Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastomaGiorgio Perilongo, Rudolf Maibach, Elisabeth Shafford, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 23, 2010
Randomized Trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the European HR-NBL1/SIOPEN studyRuth Ladenstein, Dominique Valteau-Couanet, Penelope Brock, et al.Pageof 4